Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Core Insights - Corbus Pharmaceuticals has initiated the dosing of the first participant in the PD-1 combination arm of its Phase 1 study for CRB-701, targeting solid tumors [1] - The company is experiencing a strong enrollment rate in the CRB-701 program, with a focus on advanced solid tumors associated with high Nectin-4 expression [2] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, aiming to develop innovative treatments targeting well-understood biological pathways [4] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity [4] Study Details - The Phase 1 study (NCT06265727) consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion), with the company expecting to provide a data update and establish the recommended Phase 2 dose in Q4 2025 [2] - The initial dose escalation evaluated four doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg [2] Product Information - CRB-701 (SYS6002) is a next-generation antibody-drug conjugate that utilizes a cleavable linker and a homogeneous drug-antibody ratio of 2, with MMAE as the payload [3] - Nectin-4 is recognized as a clinically validated tumor-associated antigen in urothelial cancer [3] Enrollment and Data Update - Over 100 participants have been dosed in the monotherapy cohort, with a priority focus on Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer [7] - A data update is scheduled for later this year [7]